IRADIMED (NASDAQ: IRMD) CEO sells 7,500 trust-held shares under plan

Rhea-AI Filing Summary

IRADIMED CORP director and CEO Roger E. Susi reported open-market sales of 7,500 shares of Common Stock, executed indirectly through the Phillip Susi 2008 Dynasty Trust. The sales occurred on March 23–24, 2026 at prices around $100 per share, including transactions at $99.58, $100.03, $100.71, $100.70 and $102.02 per share.

A footnote states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a scheduled selling program rather than ad hoc market timing. After the transactions, the Phillip Susi 2008 Dynasty Trust held 2,232,500 shares, while other indirect holdings included 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust and 162,950 shares in the Roger E. Susi Revocable Trust as of March 23, 2026. Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Insights

Equity analyst

IRADIMED’s CEO executed a modest, pre-planned share sale via family trusts, retaining a large remaining position.

The filing shows Roger E. Susi, IRADIMED’s CEO, president and chairman, oversaw open-market sales totaling 7,500 Common Stock shares through the Phillip Susi 2008 Dynasty Trust. Reported weighted-average prices are around $100 per share, with specific trades up to $102.02.

A key footnote explains these sales were made under a Rule 10b5-1 trading plan adopted on November 5, 2025, suggesting routine portfolio management rather than opportunistic timing. The filing also lists substantial remaining indirect holdings across multiple trusts, indicating that only a small fraction of the overall position was sold in these transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FLORIDA 32826

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		S(1)		2,950	D	$99.58(2)	2,237,050	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/23/2026		S(1)		750	D	$100.7(3)	2,236,300	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/23/2026		S(1)		1,300	D	$102.02(4)	2,235,000	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/24/2026		S(1)		1,585	D	$100.03(5)	2,233,415	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/24/2026		S(1)		915	D	$100.71(6)	2,232,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(7)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $99.02 to $100.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $100.05 to $100.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $102.00 to $102.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $99.49 to $100.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $100.53 to $100.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IRADIMED (IRMD) CEO Roger E. Susi report in this Form 4?

He reported open-market sales of 7,500 IRADIMED Common Stock shares. The transactions were executed indirectly through the Phillip Susi 2008 Dynasty Trust at prices around $100 per share over March 23–24, 2026, as part of his disclosed holdings activity.

At what prices were the IRADIMED (IRMD) insider share sales executed?

The reported weighted-average sale prices were near $100 per share. Individual trades include prices such as $99.58, $100.03, $100.70, $100.71 and $102.02, reflecting modest variation around the $100 level during the two trading days.

Were the IRADIMED (IRMD) CEO’s share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted on November 5, 2025. Such plans pre-schedule trades, indicating the transactions followed an established program rather than newly timed market decisions.

How are the sold IRADIMED (IRMD) shares held in relation to Roger E. Susi?

The 7,500 sold shares were held indirectly through the Phillip Susi 2008 Dynasty Trust. The filing notes that Susi disclaims beneficial ownership of these securities except for his pecuniary interest, clarifying how his economic exposure to the trust-held shares is characterized.

What IRADIMED (IRMD) shareholdings remain in the related trusts after these transactions?

After the reported sales, the Phillip Susi 2008 Dynasty Trust held 2,232,500 shares. As of March 23, 2026, additional indirect positions included 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust and 162,950 shares in the Roger E. Susi Revocable Trust.

Does the IRADIMED (IRMD) Form 4 show any option exercises or derivative transactions?

No derivative transactions are listed in the summarized data. All reported trades involve non-derivative Common Stock sales, and the derivative position summary is empty, indicating no option exercises or other derivative activity in this particular filing.